QR-Code

Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab

BackgroundSintilimab, a programmed cell death protein-1 (PD-1) inhibitor, has shown efficacy in non-small cell lung cancer (NSCLC), though response heterogeneity persists. Previous studies suggest that the Lung Immune Prognostic Index (LIPI) may predict prognosis and immune-related adverse events (i...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Jian Xu, Tingting Peng, Kaikai Fan, Yuxiao Dou, Lingti Kong, Ran Sang
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2025-05-01
Schriftenreihe:Frontiers in Immunology
Schlagworte:
nomograms
non-small cell lung cancer
immunotherapy
inflammation markers
predicting
sintilimab
Online-Zugang:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1569689/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge